EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor (CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 covalently attached to peptides, proteins, or attenuated pathogens generates TH1-biased immunogen-specific humoral and cellular immune responses with little inflammation. Furthermore, intranasal administration of EP67 alone increases the proportion of activated APCs in the airways. As such, we hypothesized that EP67 can act as a mucosal adjuvant. Intranasal immunization with an EP67-conjugated CTL peptide vaccine against protective MCMV epitopes M84 and pp89 increased protection of naïve female BALB/c mice against primary respiratory infection with salivary gland-derived MCMV and generated higher proportions of epitope responsive and long-lived memory precursor effector cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-conjugated CTL peptide vaccine and vehicle alone. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.
Introduction
Mucosal immunization is the generation of mucosal and systemic adaptive immune responses by administering a vaccine to mucosal tissues through the oral, nasal, sublingual, buccal, pulmonary, rectal, or vaginal routes [1] . It potentially provides several advantages over systemic immunization including (i) the generation of long-term mucosal and systemic immune responses to protect against both early and late stages of infection, (ii) the generation of long-term immune responses in mucosal tissues distal to the site of vaccine administration, (iii) a high level of "vaccine take" (immunogenicity) even with pre-existing systemic immunity, (iv) simple, relatively painless administration that requires little medical training, increases patient compliance, and has no risk of spreading blood-borne infections through needles, (v) the possibility of frequent boosting and (vi) relatively lower production costs and regulatory considerations [1] [2] [3] [4] [5] . As such, there is great interest in developing mucosal vaccines.
Licensed mucosal vaccines are predominantly oral vaccines composed of live attenuated pathogens that generate long-term protective mucosal and systemic immune responses without the associated pathogenicity [2] . Live attenuated vaccines, however, require a long time to develop, seldom produce both a safe and stable vaccine, and have the potential for pathogenic reversion [2, 4, 6] .
Mucosal vaccines composed of killed (bacteria) or inactivated (virus) pathogens (killed/inactivated vaccines) or protective fragments of the pathogen (subunit vaccines) can potentially overcome problems associated with live attenuated vaccines but require the addition of an adjuvant because they are much less immunogenic and incapable of generating cellular immune responses. Cholera toxin subunit B (CTB) is currently the only adjuvant included as part of a licensed mucosal vaccine (Dukoral: oral, killed vaccine) [7, 8] . Inclusion of a similar enterotoxin, Escherichia coli heat-labile toxin (HLT) [9] , or a "detoxified" HLT [10] with live attenuated intranasal vaccines against influenza, however, caused Bell's palsy in a number of participants during early clinical trials. Thus, numerous experimental adjuvants are being developed for clinical use with all routes of mucosal immunization.
Majority of experimental mucosal adjuvants to date are based on pathogen-associated molecular pattern (PAMP) agonists that stimulate innate immune responses through pattern recognition receptors (PRRs) [11] [12] [13] . These and other adjuvants [14] increase the generation of mucosal and systemic adaptive immune responses in clinical trials [15] but their relative ability to generate both humoral and cellular immune responses is varied or associated with high levels of inflammation and/or toxicity [2, 4] . Thus, there continues to be a great need to develop mucosal adjuvants that generate predictable humoral and cellular immune responses through distinct cellular targets and signal transduction pathways, are minimally pro-inflammatory, and are safe for massimmunization [2, 3, 16] .
In contrast to the vast majority of experimental mucosal adjuvants to date that are pathogen-derived, we previously developed a novel host-derived adjuvant, EP67, based on the C-terminal of human complement component 5a (C5a) from the innate immune system [17, 18] . EP67 is a conformationally-biased 10 amino acid peptide [18] that acts as an immunostimulant [19] [20] [21] and an adjuvant [22] [23] [24] presumably, in large part, by activating and increasing subsequent processing and presentation of conjugated immunogens by DCs through the binding and activation of the C5a receptor (C5aR/CD88) [19, 22] . EP67, or the previous analog EP54, selectively activates murine and human monocyte-derived DCs (moDCs) over neutrophils through the selective binding and activation of the C5a receptor (C5aR/CD88) on the surface of DCs [17, 18] , presents conjugated epitopes in MHC I and MHC II of human moDCs [25] , and generates TH1-biased humoral and cellular immune responses in mice against conjugated peptides, intact proteins, or attenuated pathogens after systemic administration with significantly less direct activation of neutrophils than C5a [20, [26] [27] [28] [29] . Furthermore, intranasal (IN) administration of EP67 alone increases the proportion of activated APCs in the airways of C57BL/6 mice [18] . Thus, we hypothesized that EP67 can act as a mucosal adjuvant. To test this hypothesis, we individually conjugated protective MCMV CTL epitopes (M84 and pp89) to the N-terminal of EP67 or inactive scrambled EP67 (scEP67) through a protease-labile double arginine linker. We then compared the extent to which IN immunization with M84-RR-EP67/pp89-RR-EP67 (CMV-EP67), inactive M84-RR-scEP67/pp89-RR-scEP67 (CMVscEP67), or vehicle (PBS) alone protects naïve female BALB/c mice against primary respiratory challenge with salivary gland-derived murine cytomegalovirus (SGV) and affects the generation of mucosal and systemic epitope-specific CD8 + T cells by the day of challenge with SGV.
Materials and methods

Peptides
The protective MCMV CTL epitope from M84 ( 297 AYAGLFTPL 305 ) [30] 
Intranasal immunization with CMV-EP67 and respiratory challenge with MCMV
Naïve female BALB/c mice (4-weeks old) were immunized with sterile PBS alone (15 μL) or sterile PBS containing inactive CMV-scEP67 (mixture of pp89-RR-scEP67 and M84-RR-scEP67, 50 μg each) or active CMV-EP67 (mixture of pp89-RR-EP67 and M84-RR-EP67, 50 μg each) (15 μL) on days 0, 7, and 14 by anesthetizing with isoflurane in a drop jar, holding upright, and alternating drops between nares with a 20 μL pipette. A volume of 15 μL is expected to deposit vaccine primarily in the nasal cavity [32] . Fourteen days after the final immunization (day 28), mice were challenged with a sublethal amount of SGV (5 × 10 3 PFU) by IN administration as described for administering vaccines but in a volume of sterile PBS (50 μL with a 200 μL pipette) expected to deposit MCMV in the nasal cavity and the lungs (i.e., respiratory challenge) [32] .
Extraction of MCMV from tropic organs
MCMV was extracted from tropic organs by homogenization and centrifugation [33] . Mice were sacrificed by CO 2 asphyxiation/cervical dislocation 6 days (day 34: lungs, liver, spleen) and 14 days postchallenge with SGV (day 42: salivary glands) (n = 3 mice per time point), the lungs and liver were perfused by injecting ice-cold sterile DPBS (5 mL, 25G needle) through the right ventricle of the heart, and the indicated tropic organs were isolated, weighed, suspended in Freezing Media (Section 2.3) at 10% w/v (lungs, spleen, salivary glands) or 20% w/v (liver) then stored at − 20°C. MCMV was extracted from thawed organs and stored (Section 2.3) before determining titers by plaque assay (Section 2.6).
MCMV titers
Titers of MCMV were determined by plaque assay [33, 34] . NIH/3T3 cells were grown (Section 2.3) in 24-well plates (18,000 cells/well in 0.6 mL growth media) for 2 days until~40 to 50% confluent, infected with MCMV by replacing aspirated growth media (8 wells at a time) with 10-fold serial dilutions (10 2 to 10 6 ) of thawed organ MCMV extracts diluted in Infection Media (DMEM containing glucose [4.5 g/L], sodium bicarbonate [3.7 g/L], and HI-NCS [2% v/v]; 0.2 mL/well) pipetted down the side of each well (n = 3 wells/dilution factor) and incubating (37°C/10% CO 2 ) for 4 h. Overlay Media were prepared during MCMV infection by mixing an equal volume of a pre-warmed (41°C for 10 min) agarose solution (Seakem ME Agarose [1% w/v] in dH 2 O) with a pre-warmed (41°C for 10 min) 2× growth media solution (HI-NCS [10% v/v] in 2× DMEM). After infection, growth media were quickly replaced with Overlay Media (1 mL down the side of each well) one plate at a time and plates were incubated (37°C/10% CO 2 ) for 5 days. MCMV plaques were fixed by adding Fixing Solution (Formalin [10% w/v] in sterile DPBS; 0.5 mL/well), tightly sealing stacked plates in a Ziploc® bag, and incubating at r.t. overnight. Fixing Solution was aspirated, agarose plugs were carefully removed with a steel spatula, and the remaining agarose was removed by submerging plates in cold water as needed. Plaques were visualized by incubating each well with Staining Solution (crystal violet [0.25% w/v] and ethanol [2% v/v] in dH 2 O; 0.3 mL/well) at r.t. for up to 15 min, rinsing with the wells with cold water (2×), and allowing to air dry before counting by eye. Average MCMV plaque forming units (PFU)/mL ± SD (n = 3 wells) were calculated by:
where number of plaques was taken from the organ homogenate dilution factor where 5 to 50 plaques were observed, DF was the selected dilution factor of the organ homogenate where 5 to 50 plaques were observed, and infection volume was the volume used to infect NIH/3T3 (0.2 mL). MCMV PFU/g tissue was then calculated from MCMV PFU/mL by:
where extraction volume was the volume of Freezing Media used for MCMV extraction (1 mL: lungs, spleen, salivary glands; 2 mL: liver) and mass of tropic organ was the mass of the isolated organ used in the extraction. Average MCMV PFU/g ± SD (n = 3 mice) were compared to PBS by one-way ANOVA with Dunnett's posttest. Plaque assays were repeated at least once for accuracy.
Isolation of lymphocytes (lungs) and splenocytes
Mice were sacrificed by CO 2 asphyxiation/cervical dislocation on the same day as primary respiratory challenge with SGV (14 days postimmunization), lungs were perfused by injecting ice-cold sterile DPBS (5 mL, 25G needle) through the right ventricle of the heart, and the lungs and spleen were isolated and stored on ice in sterile 15-mL conical tubes containing complete RPMI Media (cRPMI: RPMI 1640 containing
To isolate lymphocytes, lungs were transferred into a sterile 6-well cell culture plate (one lung/well), minced into small pieces using a sterile scalpel (#15, Bard-Parker), and incubated with Collagenase IV (2 mg/mL; Worthington Enzymes) in cRPMI (6 mL) at 37°C for 1 h with shaking (Vortemp 56 shaking incubator, 200 RPM). Digested lungs were triturated (18G needle) (3×) and filtered through a sterile 70-μm cell strainer into a sterile 15-mL conical tube. Filtered cells were pelleted (400 RCF, 4°C, 5 min), resuspended in RPMI 1460 (5 mL), layered onto Lympholyte-M (Cedarlane Labs; 5 mL) in a sterile 15-mL conical tube using a sterile Pasteur pipette, and centrifuged (1500 RCF w/o brakes, 4°C, 20 min). Lymphocytes were collected from the interphase with a sterile Pasteur pipette, transferred to a sterile 15-mL conical tube, resuspended in sterile DPBS (10 mL), pelleted (500 RCF, 4°C, 5 min), resuspended in cRPMI (1 mL), and stored on ice for later use.
To isolate splenocytes, spleens were transferred to a sterile 70-μm strainer inserted into a sterile 50-mL conical tube, cut into small pieces with a sterile scalpel (#15, Bard-Parker), then gently pushed through the cell strainer with the rubber end of a sterile syringe plunge while adding RPMI 1640 (30 mL). The strainer was rinsed with additional RPMI (10 mL), filtered cells were diluted to 50 mL with sterile DPBS, pelleted (500 RCF, 4°C, 10 min), resuspended in RBC lysis buffer (ACK Lysing Buffer; 4 mL), and incubated at r.t. for 7 min. cRPMI (10 mL) was added, the entire solution was triturated with a sterile 5-mL pipette to obtain a single cell suspension, and passed through a 40-μm cell strainer into a sterile 50-mL conical tube. Filtered cells were then diluted to 50 mL with sterile DPBS and pelleted (500 RCF, 4°C, 10 min.) (2×), resuspended in cRPMI (3 mL), then stored on ice for later use.
Epitope-responsiveness of CD8 + T cells
The proportion of epitope-responsive CD8 + T cells generated in the lungs and spleen on the same day as primary mucosal challenge with MCMV was compared by intracellular cytokine staining (ICS) (BD Cytofix Manual) [35] and ELISPOT (Ready-SET-Go!® kit; eBioscience) [36, 37] according to the manufacturer's instructions. For the ICS assay, pooled lymphocytes from the lungs (n = 3 mice) or splenocytes from individual mice (n = 3) were incubated with cRPMI or cRPMI containing of M84 or pp89 (2 μM) and Brefeldin A (10 μg/mL) for 6 h. . Responses were considered positive if they were ≥ 2x the number of PFU/106 splenocytes observed after treatment with growth media alone (N55 SFU/10 6 splenocytes for the current study) [38] . Average SFU/10 6 splenocytes ± SD (n = 3 mice) were compared to PBS by nonparametric (Kruskal-Wallis) oneway ANOVA with Dunn's post-test. [31] increases protection of BALB/c mice against primary systemic infection with MCMV [41, 42] . Thus, mucosal immunization of BALB/c mice with an EP67-conjugated vaccine against the protective M84 and pp89 CTL epitopes is expected to increase protection against primary mucosal infection with MCMV and provide an initial indication that EP67 can act as a mucosal adjuvant.
To determine if mucosal immunization with an EP67-conjugated CTL peptide vaccine increases protection against primary mucosal infection with MCMV, we attached M84 or pp89 to the N-terminal of EP67 or inactive scrambled EP67 (scEP67) through a subtilisin-labile double arginine linker (RR) that increases the generation of epitope-specific CTL by presumably increasing the release of CTL epitopes from EP67 within the endosomes of DCs during immunogen processing [28] . We then immunized naïve female BALB/c mice intranasally with M84-RR-EP67/ pp89-RR-EP67 (CMV-EP67), inactive M84-RR-scEP67/pp89-RR-scEP67 (CMV-scEP67), or PBS alone (vehicle), challenged with salivary glandderived MCMV (SGV) 14 days post-immunization by respiratory administration, then compared peak titers of productive MCMV in the lungs, liver, spleen, and salivary glands by plaque assay (Fig. 1A) . Mice from all treatment groups survived at least one month post-challenge during initial studies (not shown).
CMV-EP67 ( post-infection) were below our limit of detection (250 PFU/mL) for all treatment groups (not shown) as reported for primary respiratory challenge with a 100-fold higher titer of cell culture-derived MCMV [33] (5 × 10 5 PFU vs. 5 × 10 3 PFU SGV in our study). Thus, mucosal immunization with an EP67-conjugated CTL peptide vaccine increases protection against primary mucosal infection with MCMV.
Mucosal immunization with an EP67-conjugated CTL peptide vaccine increases the proportion of epitope-responsive mucosal and systemic CD8 + T cells by the day of primary challenge
A decrease in the titers of productive MCMV in tropic organs [41] and survival against lethal primary systemic challenge with MCMV [42] are proportional to the number of M84-specific or pp89-specific CD8 + T cells adoptively transferred to BALB/c mice, respectively. Thus, CMV-EP67 is expected to generate the highest proportions of epitoperesponsive mucosal and systemic CD8 + T cells compared to inactive CMV-scEP67 and vehicle alone if protection against primary respiratory infection with MCMV is mediated through CD8 + T cells.
To determine if mucosal immunization with CMV-EP67 increases the proportion of epitope-responsive mucosal and systemic CD8 + T cells, we immunized naïve female BALB/c mice IN with CMV-EP67, inactive CMV-scEP67, or PBS alone under the same dosage regimen (Fig. 1A ) and compared the proportion of M84-and pp89-responsive CD8a + cells present in the lungs and spleen by intracellular cytokine staining (ICS) on the same day as primary respiratory challenge with SGV (14 days post-immunization) ( Fig. 2A) . CMV-EP67 generated higher proportions of M84-and pp89-responsive CD8a treatment groups were observed by ICS after incubating splenocytes with M84, pp89, or media alone (not shown).
We additionally compared the proportion of M84-and pp89-responsive splenocytes that secrete IFN-γ by the potentially more sensitive ELISPOT assay [43] on the same day as primary respiratory challenge with SGV (Fig. 2C) . CMV-EP67 (Fig. 2D , black bars) generated a higher proportion of M84-and pp89-responsive splenocytes that secrete IFN-γ than PBS alone (Fig. 2D, white bars) [M84: 94 ± 15 (SD) vs. 6 ± 4 SFU/10 6 splenocytes, P = 0.0141; pp89: 60 ± 10 vs. 3 ± 3 SFU/10 6 splenocytes, P = 0.0146], whereas CMV-scEP67 (Fig. 2D, gray bars) generated lower proportions than CMV-EP67 that were statistically similar to PBS alone (Fig. 2D , white bars) [M84: 43 ± 7 (SD) vs. 6 ± 4 SFU/10 6 splenocytes, P = 0.3558; pp89: 17 ± 7 vs. 3 ± 3 SFU/10 6 splenocytes, P = 0.3594]. Given that APCs potentially secrete IFN-γ after incubation with CTL epitopes, whereas CD4 + T cells do not [44] and very few IFN-γ SFU were observed after incubating splenocytes from PBS-treated mice with M84 or pp89 (Fig. 2D, white bars) , an increase in IFN-γ SFU in the splenocytes is most likely due primarily to an increase in the number of epitope-responsive IFN-γ secreting CD8 + T cells. Thus, consistent with increased protection against primary mucosal infection with MCMV, mucosal immunization with an EP67-conjugated CTL peptide vaccine increases the proportion of epitope-responsive mucosal and systemic CD8 + T cells.
Mucosal immunization with an EP67-conjugated CTL peptide vaccine increases the proportion of memory precursor effector cells (MPEC)
Immunization provides long-term protection by generating protective memory cells that survive well beyond the contraction phase and rapidly expand in response to subsequent encounters with the same pathogen (i.e., recall response) [45] . Thus, although mucosal immunization with CMV-EP67 decreased peak titers of productive MCMV in the lungs and salivary glands after primary respiratory challenge with SGV two weeks after immunization (Fig. 1B) and increased the proportion of epitope-responsive mucosal and systemic CD8 + T cells in the lungs and spleen by the day of challenge (Figs. 2B & C) , it remained unclear whether an EP67-conjugated mucosal vaccine was likely to provide long-term protection against mucosal infection. To first determine if mucosal immunization with CMV-EP67 generates mucosal and systemic memory CD8 + T cells that recognize M84
or pp89 bound to MHC I, we administered CMV-EP67, inactive CMVscEP67, or PBS alone under the same dosage regimen (Fig. 1A) and compared the proportion of CD8a + cells present in the lungs and spleen on the same day as primary respiratory challenge with SGV (14 days post-immunization) that bind to tetramer-M84 or tetramer-pp89 by flow cytometry (Fig. 3A) . gray bars) generated lower proportions than CMV-EP67 that were statistically similar to PBS (Figs memory precursor effector cells) [46, 47] by immunogen-independent homeostatic proliferation and maintenance after clearance of an infection or vaccine [48] . Thus, to next determine if mucosal immunization with an EP67-conjugated CTL peptide vaccine is likely to generate long-lived mucosal and systemic memory cells, we further compared the proportion of CD8a 
Discussion
This study provides evidence that mucosal immunization with an EP67-conjugated CTL peptide vaccine generates mucosal and systemic memory CD8 + T cells that increase protection against primary mucosal infection with MCMV. We found that intranasal immunization with a peptide vaccine composed of two protective MCMV CTL epitopes, M84 and pp89, covalently attached to the N-terminal of EP67 through a protease-labile double arginine linker (CMV-EP67) (i) decreased peak titers of productive MCMV in the lungs and salivary glands of naïve female BALB/c mice after primary respiratory challenge with MCMV below inactive CMV-scEP67 and PBS (Fig. 1B) and (ii) generated a higher proportion of M84-and pp89-responsive CD8 + T cells in the lungs and spleen than inactive CMV-scEP67 or PBS (Fig. 2) . Although IN administration of EP67 alone to C57BL/6 mice recruits activated neutrophils and NK cells to the airways [21] that can potentially increase protection against MCMV [49] [50] [51] , both cell populations return to baseline levels within~7 days of administration even at a relatively higher dose of EP67 alone (individual dose of 240 μg EP67 vs. final individual dose of 50 μg M84-RR-EP67 and 50 μg pp89-RR-EP67 in this study) [21] . In contrast, our CMV-EP67 CTL peptide vaccine increased protection against primary respiratory challenge with SGV 14 days postimmunization (Fig. 1B) . Thus, it is unlikely that the activation of innate immunity by EP67 directly contributes to protection against primary respiratory challenge with MCMV in this study. This study also provides evidence that an EP67-conjugated mucosal vaccine is likely to provide long-term protection against primary mucosal infection. We found that respiratory immunization with CMV-EP67 increased the proportion of mucosal (lungs) and systemic (spleen) epitope-specific CD8a + cells with a cell surface phenotype found on long-lived memory CD8 + T cells (CD127 + KLRG1 − ) over inactive CMV-scEP67 and PBS (Figs. 3C & F) .
Role of EP67 in generating mucosal and systemic memory CD8 + T cells by CTL peptide vaccines
The volume used for IN administration in this study (15 μL) is expected to deposit vaccine primarily in the nasal cavity [32] . Thus, given that EP67 has increased affinity for APCs that express C5aR [18] , it is possible that EP67 generates mucosal and systemic memory CD8 + T cells against covalently attached CTL epitopes, in part, by first increasing M-cell transcytosis of the vaccine into nasal-associated lymphoid tissue (NALT) through EP67's affinity for the C5a receptor (C5aR/ CD88) that is likely expressed on the surface of NALT M-cells as it is on the surface of gut-associated lymphoid tissue (GALT) M-cells [52] . EP67 then likely generates mucosal adaptive immune responses by (i) binding and activating NALT DCs through interactions with C5aR [22, 25] to increase processing and presentation of attached epitopes and subsequent DC migration to draining lymph nodes and (ii) increasing the recruitment of monocytes, macrophages, neutrophils, and DCs into the airways through the release of cytokines and chemokines from resident and recruited DCs as observed after IN administration of EP67 alone [21] to promote vaccine uptake and subsequent generation of CD8 + T cell responses. A portion of the vaccine in the NALT is also likely carried by DCs and/or transported by lymphatic drainage to the spleen where it generates systemic cellular immune responses by activating APCs in the spleen [16] .
Role of EP67 in generating long-lived memory MPEC by CTL peptide vaccines
DCs shape CD8 + T cell differentiation through three major signals [56] [57] [58] , whereas neutralizing IL-12 or using adjuvants that generate low levels of inflammation increases the generation of long-lived MPEC [58] . Thus, given that EP67 activates C5aR-expressing DCs with minimal activation of neutrophil-mediated inflammation [18] and treating human moDCs with EP67 alone induces low levels of IL-12 in vitro (not shown), it is also possible that EP67 increases the generation of long-lived CD8 + T cells by CTL peptide vaccines, in part, by limiting neutrophil activation during APC-T cell interactions and inducing only low levels of IL-12 from DCs during CD8 + T cell differentiation.
Conclusions
In summary, our results indicate that mucosal immunization with an EP67-conjugated CTL peptide vaccine generates epitope-responsive, long-lived mucosal and systemic memory CD8 + T cells that increase protection against primary mucosal infection with MCMV. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.
